No Data
Beijing Hotgen Biotech Co.,Ltd (688068.SH): The buyback period has passed halfway, and the company has not yet implemented the buyback.
Gelonghui reported on December 30 that Beijing Hotgen Biotech Co.,Ltd (688068.SH) announced that, as of now, more than half of the repurchase period specified in the repurchase plan has elapsed, and the company has yet to implement the buyback.
Beijing Hotgen Biotech Co.,Ltd (688068.SH): Has not started the share repurchase yet.
According to Gelonghui on December 3, Beijing Hotgen Biotech Co., Ltd (688068.SH) announced that as of November 30, 2024, the company has not yet begun the repurchase.
Beijing Hotgen Biotech Co.,Ltd (688068.SH) identified Chen Jiangguo as a core technical staff member.
Beijing Hotgen Biotech Co., Ltd (688068.SH) announced that Chen Jianguo has been newly recognized as a core technical personnel of the company, replacing the original core technical...
Beijing Hotgen Biotech Co., Ltd (688068.SH) and its subsidiaries recently obtained 18 qualifications.
Beijing Hotgen Biotech Co., Ltd (688068.SH) issued an announcement that the company and its subsidiaries have recently obtained domestic medical instruments registration certificates.
Hejing Biotech: Beijing Hejing Biotechnology Co., Ltd. Report for the Third Quarter of 2024
Beijing Hejing Biotechnology Co., Ltd. Report for the Third Quarter of 2024
